Page last updated: 2024-08-21

quinazolines and Pleural Effusion

quinazolines has been researched along with Pleural Effusion in 10 studies

Research

Studies (10)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	3 (30.00)	29.6817
2010's	7 (70.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Dong, Z; Gao, H; Hu, H; Li, X; Liu, B; Liu, X; Liu, Y; Shi, W; Sun, Y; Tang, C; Xu, H; Zhu, G	1
Chang, S; Choi, BW; Han, K; Hong, YJ; Hur, J; Kim, YJ; Lee, HJ	1
Boers-Sonderen, MJ; Mulder, SF; Punt, CJ; van der Heijden, HF; van Herpen, CM; Vissers, KC	1
Bonetti, A; Giuliani, J; Martelli, S; Remo, A	1
Acquaviva, G; Brand, T; Brandes, AA; Cavallo, G; de Biase, D; Degli Esposti, R; Di Battista, M; Genestreti, G; Pession, A; Tallini, G; Visani, M	1
Caicun, Z; Jian, G; Jie, Z; Liang, T; Ling, Z; Qinfang, D; Songwen, Z	1
Fukudo, M; Inui, K; Irisa, K; Kim, YH; Masago, K; Mio, T; Mishima, M; Sakamori, Y; Terada, T; Togashi, Y	1
Edakuni, N; Inayama, M; Kakiuchi, S; Muguruma, H; Nakataki, E; Nishikubo, N; Ohtsuka, S; Sone, S; Tomimoto, H; Yano, S	1
Chowbay, B; Goh, JW; Lee, P; Mancer, K; Tan, PH; Toh, CK	1
Ang, K; Herbst, RS; Itasaka, S; Jürgensmeier, JM; Komaki, R; Milas, L; O'Reilly, MS; Ryan, A; Shibuya, K; Shintani, T	1

Trials

2 trial(s) available for quinazolines and Pleural Effusion

Article	Year
A phase II study of cediranib as palliative treatment in patients with symptomatic malignant ascites or pleural effusion. Targeted oncology, 2014, Volume: 9, Issue:4 Topics: Administration, Oral; Aged; Antineoplastic Agents; Ascites; Disease Progression; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Palliative Care; Paracentesis; Pleural Effusion; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Time Factors; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-1	2014
Plasma and pleural fluid pharmacokinetics of erlotinib and its active metabolite OSI-420 in patients with non-small-cell lung cancer with pleural effusion. Clinical lung cancer, 2011, Volume: 12, Issue:5 Topics: Aged; Aged, 80 and over; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Chromatography, High Pressure Liquid; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Pleural Effusion; Protein Kinase Inhibitors; Quinazolines; Time Factors	2011

Article

Year

A phase II study of cediranib as palliative treatment in patients with symptomatic malignant ascites or pleural effusion.

Targeted oncology, 2014, Volume: 9, Issue:4

Topics: Administration, Oral; Aged; Antineoplastic Agents; Ascites; Disease Progression; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Palliative Care; Paracentesis; Pleural Effusion; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Time Factors; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-1

2014

Plasma and pleural fluid pharmacokinetics of erlotinib and its active metabolite OSI-420 in patients with non-small-cell lung cancer with pleural effusion.

Clinical lung cancer, 2011, Volume: 12, Issue:5

Topics: Aged; Aged, 80 and over; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Chromatography, High Pressure Liquid; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Pleural Effusion; Protein Kinase Inhibitors; Quinazolines; Time Factors

2011

Other Studies

8 other study(ies) available for quinazolines and Pleural Effusion

Article	Year
Droplet digital PCR improved the EGFR mutation diagnosis with pleural fluid samples in non-small-cell lung cancer patients. Clinica chimica acta; international journal of clinical chemistry, 2017, Volume: 471 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crown Ethers; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Particle Size; Pleural Effusion; Polymerase Chain Reaction; Quinazolines	2017
Adverse Prognostic CT Findings for Patients With Advanced Lung Adenocarcinoma Receiving First-Line Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapy. AJR. American journal of roentgenology, 2018, Volume: 210, Issue:1 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pleural Effusion; Prognosis; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Tomography, X-Ray Computed; Young Adult	2018
Primary TKI resistance in advanced non-small cell lung cancer with EGFR mutation: an open question. Tumori, 2015, Jul-24, Volume: 101, Issue:4 Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Female; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Pleural Effusion; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Tomography, X-Ray Computed	2015
Epidermal Growth Factor Receptor (EGFR) Mutation in Exon 19 (p.E749Q) Confers Resistance to Gefitinib in One Patient With Lung Adenocarcinoma. Clinical lung cancer, 2017, Volume: 18, Issue:3 Topics: Adenocarcinoma; Aged; DNA Mutational Analysis; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Dyspnea; ErbB Receptors; Exons; Gefitinib; High-Throughput Nucleotide Sequencing; Humans; Lung Neoplasms; Male; Mutation; Pleural Effusion; Protein Kinase Inhibitors; Quinazolines	2017
Prediction of epidermal growth factor receptor mutations in the plasma/pleural effusion to efficacy of gefitinib treatment in advanced non-small cell lung cancer. Journal of cancer research and clinical oncology, 2010, Volume: 136, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Pleural Effusion; Predictive Value of Tests; Quinazolines; Survival Analysis	2010
Retreatment of lung adenocarcinoma patients with gefitinib who had experienced favorable results from their initial treatment with this selective epidermal growth factor receptor inhibitor: a report of three cases. Oncology research, 2005, Volume: 15, Issue:2 Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Disease Progression; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pleural Effusion; Quinazolines; Recurrence; Retreatment; Time Factors	2005
An inflammatory response with worsening of pleural effusion on treatment with erlotinib in non-small cell lung cancer. Acta oncologica (Stockholm, Sweden), 2007, Volume: 46, Issue:2 Topics: Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Middle Aged; Pleural Effusion; Pneumonia; Protein Kinase Inhibitors; Quinazolines; Radiography; Treatment Outcome	2007
Targeted therapy against VEGFR and EGFR with ZD6474 enhances the therapeutic efficacy of irradiation in an orthotopic model of human non-small-cell lung cancer. International journal of radiation oncology, biology, physics, 2007, Dec-01, Volume: 69, Issue:5 Topics: Animals; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; DNA Repair; Epidermal Growth Factor; ErbB Receptors; Feasibility Studies; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Neovascularization, Pathologic; Piperidines; Pleural Effusion; Quinazolines; Radiation Tolerance; Radiation-Sensitizing Agents; Receptors, Vascular Endothelial Growth Factor; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays	2007